应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
GKOS Glaukos Corp
休市中 11-20 16:00:00 EST
237.31
-0.79
-0.33%
盘后
237.31
+0.00
0.00%
19:30 EST
最高
244.55
最低
233.40
成交量
108.96万
今开
238.87
昨收
238.10
日振幅
4.68%
总市值
139.97亿
流通市值
135.08亿
总股本
5,898万
成交额
2.59亿
换手率
1.91%
流通股本
5,692万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
异动解读|Glaukos Corp盘中上涨5.01%,强劲财报与上调指引持续发酵
行情直击 · 11-10
异动解读|Glaukos Corp盘中上涨5.01%,强劲财报与上调指引持续发酵
异动解读|Glaukos Corp盘中下跌9.95%,财报利好后股价回吐
行情直击 · 11-06
异动解读|Glaukos Corp盘中下跌9.95%,财报利好后股价回吐
异动解读|Glaukos Corp盘中上涨15.61%,三季度业绩超预期且全年销售指引大幅上修
行情直击 · 10-29
异动解读|Glaukos Corp盘中上涨15.61%,三季度业绩超预期且全年销售指引大幅上修
异动解读|Glaukos Corp盘前上涨13.54%,全年销售指引大幅上修叠加三季度业绩超预期
行情直击 · 10-29
异动解读|Glaukos Corp盘前上涨13.54%,全年销售指引大幅上修叠加三季度业绩超预期
异动解读|Glaukos Corp夜盘上涨18.37%,全年指引大幅上修叠加三季度业绩超预期
行情直击 · 10-29
异动解读|Glaukos Corp夜盘上涨18.37%,全年指引大幅上修叠加三季度业绩超预期
异动解读|Glaukos Corp盘后上涨7.48%,财报预期与临床进展提振情绪
行情直击 · 10-29
异动解读|Glaukos Corp盘后上涨7.48%,财报预期与临床进展提振情绪
财报前瞻 | Glaukos Corp本季度营收预计增长37.14%,机构观点偏多
财报Agent · 10-21
财报前瞻 | Glaukos Corp本季度营收预计增长37.14%,机构观点偏多
异动解读|Glaukos盘中上涨6.57%,2026年销售指引大幅上调
行情直击 · 10-07
异动解读|Glaukos盘中上涨6.57%,2026年销售指引大幅上调
异动解读|Glaukos Corp盘中上涨5.46%,Q2业绩大超预期叠加多家机构上调目标价
行情直击 · 08-08
异动解读|Glaukos Corp盘中上涨5.46%,Q2业绩大超预期叠加多家机构上调目标价
异动解读|Glaukos Corp盘中上涨5.21%,二季度营收与全年指引双双大超预期
行情直击 · 07-31
异动解读|Glaukos Corp盘中上涨5.21%,二季度营收与全年指引双双大超预期
异动解读|Glaukos Corp盘前上涨9.49%,二季度营收与全年指引双双大超预期
行情直击 · 07-30
异动解读|Glaukos Corp盘前上涨9.49%,二季度营收与全年指引双双大超预期
异动解读 | 二季度营收与指引双超预期,Glaukos Corp夜盘大涨6.33%
异动解读 · 07-30
异动解读 | 二季度营收与指引双超预期,Glaukos Corp夜盘大涨6.33%
异动解读|Glaukos Corp夜盘上涨6.33%,二季度营收与指引双双大超预期
行情直击 · 07-30
异动解读|Glaukos Corp夜盘上涨6.33%,二季度营收与指引双双大超预期
异动解读 | 二季度营收远超预期,Glaukos Corp盘后大涨9.77%
异动解读 · 07-30
异动解读 | 二季度营收远超预期,Glaukos Corp盘后大涨9.77%
Glaukos第二季度销售额达1.856亿美元,远超市场预期的1.509亿美元
投资观察 · 07-30
Glaukos第二季度销售额达1.856亿美元,远超市场预期的1.509亿美元
异动解读|Glaukos Corp盘后上涨5.05%,管线里程碑与财报催化共振
行情直击 · 07-30
异动解读|Glaukos Corp盘后上涨5.05%,管线里程碑与财报催化共振
异动解读|Glaukos Corp盘中上涨5.07%,管线里程碑叠加财报预期提振
行情直击 · 07-30
异动解读|Glaukos Corp盘中上涨5.07%,管线里程碑叠加财报预期提振
Glaukos宣布完成Preserflo™微型引流器510(k)关键性研究患者入组
美股速递 · 07-27
Glaukos宣布完成Preserflo™微型引流器510(k)关键性研究患者入组
财报前瞻|Glaukos Corp本季度营收预计增30.68%,机构观点偏多
财报Agent · 07-22
财报前瞻|Glaukos Corp本季度营收预计增30.68%,机构观点偏多
Glaukos宣布完成针对蠕形螨睑缘炎药物Glk-321的二期临床试验患者招募
美股速递 · 06-25
Glaukos宣布完成针对蠕形螨睑缘炎药物Glk-321的二期临床试验患者招募
加载更多
公司概况
公司名称:
Glaukos Corp
所属市场:
NYSE
上市日期:
--
主营业务:
Glaukos Corporation于1998年7月14日在特拉华州注册成立。该公司是一家眼科制药和医疗技术公司,专注于开发新型无滴剂疗法,并将相关产品商业化,用于治疗青光眼、角膜疾病和视网膜疾病。他们首先开发了微创青光眼手术(MIGS)作为传统青光眼治疗模式的替代方案,并于2012年推出了他们的第一台MIGS设备。他们还提供商业化的专有生物激活药物疗法,用于治疗罕见的角膜疾病圆锥角膜,该疗法于2016年获得美国食品和药物管理局(FDA)的批准。他们正在开发一系列平台,以支持正在进行的制药和医疗器械创新。
发行价格:
--
{"stockData":{"symbol":"GKOS","market":"US","secType":"STK","nameCN":"Glaukos Corp","latestPrice":237.31,"timestamp":1795208400000,"preClose":238.1,"halted":0,"volume":1089561,"hourTrading":{"tag":"盘后","latestPrice":237.31,"preClose":237.31,"latestTime":"19:30 EST","volume":77993,"amount":18508484.01,"timestamp":1795221006256,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.00331793364132714,"floatShares":56920246,"shares":58983937,"eps":-2.909669,"marketStatus":"休市中","change":-0.79,"latestTime":"11-20 16:00:00 EST","open":238.87,"high":244.545,"low":233.4,"amount":258793552.90734,"amplitude":0.046808,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.909669,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1795424400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1435204800000,"exchange":"NYSE","adjPreClose":238.1,"preHourTrading":{"tag":"盘前","latestPrice":237,"preClose":238.1,"latestTime":"09:24 EST","volume":651,"amount":154707.77385,"timestamp":1795184697686,"change":-1.1,"changeRate":-0.00462,"amplitude":0.101722},"postHourTrading":{"tag":"盘后","latestPrice":237.31,"preClose":237.31,"latestTime":"19:30 EST","volume":77993,"amount":18508484.01,"timestamp":1795221006256,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.3589432292300465,"impliedVol":0.5774,"impliedVolPercentile":0.498},"requestUrl":"/m/hq/s/GKOS","defaultTab":"news","newsList":[{"id":"1125905227","title":"异动解读|Glaukos Corp盘中上涨5.01%,强劲财报与上调指引持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1125905227","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125905227?lang=zh_cn&edition=full","pubTime":"2026-11-10 00:15","pubTimestamp":1794240908,"startTime":"0","endTime":"0","summary":"11月10日,Glaukos Corp盘中上涨5.01%,报235.52美元,成交额4187.87万美元。消息面上,公司此前披露的第三季度业绩显著好于预期,并上调全年销售指引,利好影响仍在延续。公司第三季度调整后每股收益0.47美元,上年同期亏损0.16美元,市场原预期亏损0.10美元;营收2.11亿美元,高于预期的1.68亿美元。公司同时将全年营收指引由6.80亿至7.00亿美元上调至7.75亿至7.85亿美元,并给出下一年10亿美元营收目标,高于市场预期。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报超预期,股价强势上扬","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GKOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133520348","title":"异动解读|Glaukos Corp盘中下跌9.95%,财报利好后股价回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1133520348","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133520348?lang=zh_cn&edition=full","pubTime":"2026-11-06 02:28","pubTimestamp":1793903328,"startTime":"0","endTime":"0","summary":"11月6日,Glaukos Corp盘中下跌9.95%,报222.16美元,成交额2.66亿美元。公开消息面上,公司此前披露第三季度业绩显著好于预期,并上调全年销售指引,但最新交易日股价出现回吐。公司第三季度调整后每股收益0.47美元,去年同期亏损0.16美元,市场原预期亏损0.10美元;营收2.11亿美元,高于预期的1.68亿美元。公司并将全年营收指引由6.80亿至7.00亿美元上调至7.75亿至7.85亿美元,同时给出下一年10亿美元营收目标,高于市场预期。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报超预期却遭大跌,Glaukos盘中重挫","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GKOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118618355","title":"异动解读|Glaukos Corp盘中上涨15.61%,三季度业绩超预期且全年销售指引大幅上修","url":"https://stock-news.laohu8.com/highlight/detail?id=1118618355","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118618355?lang=zh_cn&edition=full","pubTime":"2026-10-29 21:35","pubTimestamp":1793280959,"startTime":"0","endTime":"0","summary":"10月29日,Glaukos Corp盘中上涨15.61%,报217.74美元,成交额1.01亿美元。此次异动的核心催化,是公司三季度业绩显著超预期,并同步上调全年销售指引。数据显示,公司三季度调整后每股收益为0.47美元,明显好于市场预期的亏损0.09美元;销售额为2.11亿美元,高于预期的1.68亿美元。业绩与指引双双超预期后,多家机构上调目标价,进一步强化市场乐观情绪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Glaukos业绩超预期,股价大涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GKOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150105127","title":"异动解读|Glaukos Corp盘前上涨13.54%,全年销售指引大幅上修叠加三季度业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1150105127","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150105127?lang=zh_cn&edition=full","pubTime":"2026-10-29 16:12","pubTimestamp":1793261523,"startTime":"0","endTime":"0","summary":"10月29日,Glaukos Corp盘前上涨13.54%,报214.0美元,成交额1.09万美元。此次异动的核心催化来自公司最新披露的三季度业绩与全年指引同步超预期。公司三季度调整后每股收益为0.47美元,明显好于市场预期的亏损0.09美元;销售额为2.11亿美元,高于预期的1.68亿美元。更关键的是,公司预计全年净销售额为7.75亿至7.85亿美元,显著高于市场预期的6.917亿美元,也高于此前给出的6.80亿至7.00亿美元区间,显示主营业务放量与盈利改善趋势强化。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Glaukos上调全年指引,盘前股价大涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GKOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106175734","title":"异动解读|Glaukos Corp夜盘上涨18.37%,全年指引大幅上修叠加三季度业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1106175734","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106175734?lang=zh_cn&edition=full","pubTime":"2026-10-29 08:30","pubTimestamp":1793233827,"startTime":"0","endTime":"0","summary":"10月29日,Glaukos Corp夜盘上涨18.37%,报214.76美元,成交额1.36万美元。此次异动的核心催化来自公司最新披露的业绩与指引同步超预期。公司三季度调整后每股收益0.47美元,显著好于市场预期的亏损0.09美元;销售额2.11亿美元,高于预期的1.68亿美元。更关键的是,公司预计年度净销售额为7.75亿至7.85亿美元,明显高于此前市场预期的6.917亿美元,也较7月给出的6.80亿至7.00亿美元指引进一步上修,显示主营业务放量与盈利改善趋势同时强化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"业绩指引双超预期,Glaukos夜盘大涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GKOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127163260","title":"异动解读|Glaukos Corp盘后上涨7.48%,财报预期与临床进展提振情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1127163260","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127163260?lang=zh_cn&edition=full","pubTime":"2026-10-29 04:08","pubTimestamp":1793218130,"startTime":"0","endTime":"0","summary":"10月29日,Glaukos Corp盘后上涨7.48%,报195.55美元,成交额1001.83万美元。同时,公司10月上旬披露,iDose TR四期试验达到主要终点,联合白内障手术可显著降低日间眼压,且安全性良好;Epioxa三年期延展研究也显示疗效持续、耐受性稳定,进一步强化其眼科产品管线兑现预期。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报与临床双重利好,Glaukos盘后大涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GKOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140115913","title":"财报前瞻 | Glaukos Corp本季度营收预计增长37.14%,机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1140115913","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140115913?lang=zh_cn&edition=full","pubTime":"2026-10-21 10:38","pubTimestamp":1792550298,"startTime":"0","endTime":"0","summary":"Glaukos Corp将于2026年10月28日发布财报。市场一致预期本季度Glaukos Corp营收为1.68亿美元,同比增长37.14%;预计调整后每股收益为-0.09美元,同比改善43.75%;预计息税前利润为-602.26万美元,同比改善62.08%。近期多家机构对Glaukos Corp持偏多态度,占比较高的观点认为,公司本季度营收预计增长与利润率改善趋势明确,驱动来自青光眼微创器械渗透率提升与国际拓展。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 | Glaukos Corp本季度营收预计增长37.14%,机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GKOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192118702","title":"异动解读|Glaukos盘中上涨6.57%,2026年销售指引大幅上调","url":"https://stock-news.laohu8.com/highlight/detail?id=1192118702","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192118702?lang=zh_cn&edition=full","pubTime":"2026-10-07 21:54","pubTimestamp":1791381291,"startTime":"0","endTime":"0","summary":"10月7日,Glaukos Corp盘中上涨6.57%,报172.205美元/股,成交额3017.83万美元。Glaukos Corporation是一家眼科制药和医疗技术公司,专注于开发新型无滴剂疗法,并将其商业化用于治疗青光眼、角膜疾病和视网膜疾病。公司于2012年推出首款微创青光眼手术设备,并于2016年获得FDA批准上市用于治疗圆锥角膜的专有生物激活药物疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Glaukos盘中上扬,2026年销售指引大超预期","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GKOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177498121","title":"异动解读|Glaukos Corp盘中上涨5.46%,Q2业绩大超预期叠加多家机构上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1177498121","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177498121?lang=zh_cn&edition=full","pubTime":"2026-08-08 03:57","pubTimestamp":1786132625,"startTime":"0","endTime":"0","summary":"8月8日,Glaukos Corp盘中上涨5.46%,报180.25美元/股,成交额1.05亿美元。消息面上,公司此前发布的Q2财报大幅超出市场预期:调整后每股亏损收窄至0.14美元,优于市场预期的亏损0.22美元;营收达1.856亿美元,较预期的1.509亿美元高出约23%。同时,公司将全年营收指引上调至6.8亿至7亿美元,远高于市场此前预估的6.3亿美元。财报发布后,多家机构密集上调目标价:Needham将目标价从150美元大幅调升至201美元,HC Wainwright上调至195美元,均维持买入评级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GKOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172806983","title":"异动解读|Glaukos Corp盘中上涨5.21%,二季度营收与全年指引双双大超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1172806983","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172806983?lang=zh_cn&edition=full","pubTime":"2026-07-31 00:22","pubTimestamp":1785428535,"startTime":"0","endTime":"0","summary":"7月30日,Glaukos Corp盘中上涨5.21%,报169.765美元/股,成交额2.23亿美元。消息面上,公司于盘后发布第二季度财报,营收与全年指引均大幅超出市场预期,成为推动股价走强的核心催化剂。同时,公司将全年销售指引大幅上调至6.8亿至7.0亿美元,远超FactSet此前6.3亿美元的一致预期。这已是公司连续第二个季度营收显著超预期,延续高增态势。此外,Needham将目标价从150美元大幅上调至201美元并维持买入评级,进一步提振市场情绪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GKOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141459642","title":"异动解读|Glaukos Corp盘前上涨9.49%,二季度营收与全年指引双双大超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1141459642","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141459642?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:22","pubTimestamp":1785403358,"startTime":"0","endTime":"0","summary":"7月30日,Glaukos Corp盘前上涨9.49%,报177.0美元/股。消息面上,公司于盘后发布第二季度财报,营收与全年指引均大幅超出市场预期,成为股价走强的核心催化剂。此外,公司将全年销售指引大幅上调至6.8亿至7.0亿美元,远超FactSet此前6.3亿美元的一致预期。这已是公司连续第二个季度营收显著超预期,延续高增态势。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GKOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147377509","title":"异动解读 | 二季度营收与指引双超预期,Glaukos Corp夜盘大涨6.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=1147377509","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147377509?lang=zh_cn&edition=full","pubTime":"2026-07-30 09:36","pubTimestamp":1785375397,"startTime":"0","endTime":"0","summary":"Glaukos Corp夜盘交易时段股价大涨6.33%,引发市场关注。消息面上,公司于盘后发布了第二季度财报,业绩表现远超市场预期。数据显示,公司第二季度销售额达到1.856亿美元,较市场普遍预期的1.509亿美元高出约23%;调整后每股亏损0.14美元,优于预期的亏损0.22美元,亏损幅度同比也明显收窄。此外,公司还将全年销售指引上调至6.8亿至7.0亿美元,大幅超出FactSet此前6.3亿美元的一致预期。营收与指引双双亮眼,成为推动股价在夜盘持续走强的核心催化剂。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GKOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129491890","title":"异动解读|Glaukos Corp夜盘上涨6.33%,二季度营收与指引双双大超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1129491890","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129491890?lang=zh_cn&edition=full","pubTime":"2026-07-30 09:34","pubTimestamp":1785375277,"startTime":"0","endTime":"0","summary":"7月30日,Glaukos Corp夜盘上涨6.33%,报171.9美元/股。消息面上,公司于盘后发布第二季度财报,营收与全年指引均大幅超出市场预期,成为推动股价走高的核心催化剂。此外,公司将全年销售指引上调至6.8亿至7.0亿美元区间,远超FactSet此前6.3亿美元的一致预期。这已是公司连续第二个季度营收大幅超预期,Q1销售额1.506亿美元同样显著好于1.37亿美元的预期,延续高增态势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Glaukos Corp夜盘上涨6.33%,二季度营收与指引双双大超预期","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GKOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124010311","title":"异动解读 | 二季度营收远超预期,Glaukos Corp盘后大涨9.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=1124010311","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124010311?lang=zh_cn&edition=full","pubTime":"2026-07-30 04:50","pubTimestamp":1785358225,"startTime":"0","endTime":"0","summary":"Glaukos Corp今日盘后股价大涨9.77%,引发市场广泛关注。消息面上,公司于盘后发布了第二季度财报,数据显示销售额达到1.856亿美元,显著高于市场普遍预期的1.509亿美元,成为推动盘后股价飙升的核心催化剂。尽管公司本季度录得净亏损1840万美元,但营收端的强劲表现极大地提振了投资者信心。管线里程碑与财报超预期形成共振,共同推动盘后股价大幅走高。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GKOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168687286","title":"Glaukos第二季度销售额达1.856亿美元,远超市场预期的1.509亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1168687286","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168687286?lang=zh_cn&edition=full","pubTime":"2026-07-30 04:21","pubTimestamp":1785356496,"startTime":"0","endTime":"0","summary":"Glaukos公布第二季度财报,净亏损1840万美元。但与此同时,公司销售额表现亮眼,达到1.856亿美元,显著高于市场普遍预期的1.509亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1878469433.USD","IE0009354923.USD","BK4548","GKOS","LU2065731478.USD","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136642919","title":"异动解读|Glaukos Corp盘后上涨5.05%,管线里程碑与财报催化共振","url":"https://stock-news.laohu8.com/highlight/detail?id=1136642919","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136642919?lang=zh_cn&edition=full","pubTime":"2026-07-30 04:06","pubTimestamp":1785355619,"startTime":"0","endTime":"0","summary":"7月29日,Glaukos Corp盘后上涨5.05%,报167.0美元/股,成交额236.89万美元。机构层面,Truist将目标价从160美元上调至180美元并维持买入评级,Needham亦多次上调目标价;尽管瑞银近日将评级下调至中性,但整体市场情绪偏多,FactSet统计均值目标价为163.85美元。管线进展与财报催化形成共振,推动盘后进一步走高。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GKOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198278176","title":"异动解读|Glaukos Corp盘中上涨5.07%,管线里程碑叠加财报预期提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1198278176","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198278176?lang=zh_cn&edition=full","pubTime":"2026-07-30 01:45","pubTimestamp":1785347131,"startTime":"0","endTime":"0","summary":"7月29日,Glaukos Corp盘中上涨5.07%,报158.775美元/股,成交额1.95亿美元。同时,市场对公司即将发布的季度财报持乐观预期,一致预期本季度营收约1.51亿美元,同比增长30.68%,延续高增态势。尽管瑞银近日将公司评级从买入下调至中性,但Truist等多家机构维持买入评级并上调目标价,整体市场情绪偏多。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GKOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176482715","title":"Glaukos宣布完成Preserflo™微型引流器510(k)关键性研究患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1176482715","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176482715?lang=zh_cn&edition=full","pubTime":"2026-07-27 19:04","pubTimestamp":1785150246,"startTime":"0","endTime":"0","summary":"Glaukos公司正式宣告,其针对Preserflo™微型引流器的510(k)关键性研究已完成患者入组工作。这一里程碑式的进展,标志着该产品上市进程迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1878469433.USD","IE0009354923.USD","BK4548","BK4082","LU2065731478.USD","GKOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101767534","title":"财报前瞻|Glaukos Corp本季度营收预计增30.68%,机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1101767534","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101767534?lang=zh_cn&edition=full","pubTime":"2026-07-22 12:13","pubTimestamp":1784693604,"startTime":"0","endTime":"0","summary":"Glaukos Corp将于2026年07月29日发布财报,市场关注收入增速与亏损收窄节奏。市场一致预期Glaukos Corp本季度收入约1.51亿美元,同比增长30.68%;调整后每股收益约-0.22美元,同比改善15.63%。市场预计本季度公司收入约1.51亿美元、同比增长30.68%,延续上季41.16%的高增节奏,核心来源仍然是青光眼相关产品的放量贡献。近期机构观点整体偏多,目标价普遍上调并维持买入评级,显示看多意见占据明显多数。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻|Glaukos Corp本季度营收预计增30.68%,机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GKOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109471401","title":"Glaukos宣布完成针对蠕形螨睑缘炎药物Glk-321的二期临床试验患者招募","url":"https://stock-news.laohu8.com/highlight/detail?id=1109471401","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109471401?lang=zh_cn&edition=full","pubTime":"2026-06-25 19:02","pubTimestamp":1782385354,"startTime":"0","endTime":"0","summary":"Glaukos公司已顺利完成其候选药物Glk-321针对蠕形螨睑缘炎适应症的第二阶段临床试验的患者入组工作。这一进展标志着该疗法在临床开发路径上迈出了关键一步,为后续评估其有效性与安全性奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1878469433.USD","BK4082","BK4548","LU2065731478.USD","GKOS","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.glaukos.com","stockEarnings":[{"period":"1week","weight":-0.0342},{"period":"1month","weight":0.3419},{"period":"3month","weight":0.2835},{"period":"6month","weight":0.9738},{"period":"1year","weight":1.4928},{"period":"ytd","weight":1.1018}],"compareEarnings":[{"period":"1week","weight":-0.0856},{"period":"1month","weight":-0.1077},{"period":"3month","weight":-0.0991},{"period":"6month","weight":-0.0749},{"period":"1year","weight":0.0571},{"period":"ytd","weight":0.0116}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Glaukos Corporation于1998年7月14日在特拉华州注册成立。该公司是一家眼科制药和医疗技术公司,专注于开发新型无滴剂疗法,并将相关产品商业化,用于治疗青光眼、角膜疾病和视网膜疾病。他们首先开发了微创青光眼手术(MIGS)作为传统青光眼治疗模式的替代方案,并于2012年推出了他们的第一台MIGS设备。他们还提供商业化的专有生物激活药物疗法,用于治疗罕见的角膜疾病圆锥角膜,该疗法于2016年获得美国食品和药物管理局(FDA)的批准。他们正在开发一系列平台,以支持正在进行的制药和医疗器械创新。","yearOnYearQuotes":[{"month":1,"riseRate":0.909091,"avgChangeRate":0.08374},{"month":2,"riseRate":0.636364,"avgChangeRate":-0.005569},{"month":3,"riseRate":0.545455,"avgChangeRate":-0.03024},{"month":4,"riseRate":0.545455,"avgChangeRate":0.040364},{"month":5,"riseRate":0.545455,"avgChangeRate":-0.003117},{"month":6,"riseRate":0.909091,"avgChangeRate":0.132641},{"month":7,"riseRate":0.666667,"avgChangeRate":0.032986},{"month":8,"riseRate":0.5,"avgChangeRate":0.051626},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.036372},{"month":10,"riseRate":0.583333,"avgChangeRate":0.023095},{"month":11,"riseRate":0.5,"avgChangeRate":0.027838},{"month":12,"riseRate":0.545455,"avgChangeRate":0.013516}],"exchange":"NYSE","name":"Glaukos Corp","nameEN":"Glaukos"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Glaukos Corp(GKOS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Glaukos Corp(GKOS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Glaukos Corp,GKOS,Glaukos Corp股票,Glaukos Corp股票老虎,Glaukos Corp股票老虎国际,Glaukos Corp行情,Glaukos Corp股票行情,Glaukos Corp股价,Glaukos Corp股市,Glaukos Corp股票价格,Glaukos Corp股票交易,Glaukos Corp股票购买,Glaukos Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Glaukos Corp(GKOS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Glaukos Corp(GKOS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}